Nitrogen Containing Patents (Class 514/471)
-
Publication number: 20090062241Abstract: The invention relates to a method of manufacture of fast-disintegrating solid dosage forms, characterized in that one or more structure building components in mixed solid powder form are dosed into cavities of blister packs or moulds, the remaining components dissolved in water dosed and added to the powder to form a moistened, plasticized mass, frozen to below ?20° C. , and the water sublimed in high vacuum. In this way solid dosage forms are obtainable with a similar porous structure as usually result from freeze-drying processes, but the process requires much less water, which means considerably less time and less energy.Type: ApplicationFiled: October 27, 2005Publication date: March 5, 2009Inventor: Kurt Heinz Bauer
-
Publication number: 20090062383Abstract: The present invention relates to salts of substituted allophanates, methods for their production, medicaments containing said compounds and the use of said compound for the production of medicaments.Type: ApplicationFiled: May 17, 2006Publication date: March 5, 2009Applicant: Gruenenthal GmbHInventors: Robert Frank, Ruth Jostock, Hans Schick, Fritz Theil, Olga Groeger, Rene Kudick, Helmut Sonnenschein, Birgitta Henkel
-
Patent number: 7495023Abstract: The present invention relates to thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of using such compounds to prevent and treat protozoan infections such as trypanosomiasis, malaria and leishmaniasis. The compounds also find use in inhibiting cysteine proteases associated with carcinogenesis, including cathepsins B and L.Type: GrantFiled: March 18, 2005Date of Patent: February 24, 2009Assignee: The Regents of the University of CaliforniaInventors: Fred E. Cohen, Xiaohui Du, Chun Guo, James H. McKerrow
-
Patent number: 7491740Abstract: Methods of use and pharmaceutical compositions for a genus of low molecular weight compounds comprising optionally substituted isoxazoline ring systems that act as inhibitors of MIF (macrophage migration inhibitory factor) are disclosed. Specifically, the compounds are useful for treating a variety of diseases involving inflammatory activity or pro-inflammatory cytokine responses, such as autoimmune diseases (including rheumatiod arthritis, insulin-dependent diabetes, multiple sclerosis, graft versus host disease, lupus syndromes), asthma, arthritis, ARDS, psoriasis, interleukin-2 toxicity, proliferative vascular disease, and various forms of sepsis and septic shock, and other conditions characterized by underlying MIF responses including, for instance, tumor growth and neovascularization (angiogenesis).Type: GrantFiled: June 10, 2002Date of Patent: February 17, 2009Assignee: Cytokine PharmaSciences, Inc.Inventor: Yousef Al-Abed
-
Publication number: 20090042978Abstract: The present invention describes the action of a new family of drugs against a number of Leishmania species and Trypanosona cruzi, for the treatment of cutaneous, mucocutaneous and visceral leishmaniosis as well as tripanosomosis. In vitro assays and studies conducted in animal models and in human patients demonstrated that the compounds had a higher activity compared to drugs in clinical use against Leishmania mexicana amazonensis, L. donovani infantum, L. braziliensis braziliensis and Trypanosoma cruzi. The pharmaceutical activity of compositions based on such family of compounds was evidenced and supports its human and veterinary application for the treatment of the above-mentioned diseases by using different administration routes.Type: ApplicationFiled: September 18, 2006Publication date: February 12, 2009Applicant: CENTRO DE BIOACTIVOS QUIMICOSInventors: Nilo Ramon Castanedo Cancio, Sergio Sifontes Rodriguez, Lianet Monzote Fidalgo, Yamile Lopez Hernandez, Ana Margarita Montalvo Alvarez, Juan Francisco Infante Bourzac, Ervelio Eliseo Olazabal Manso
-
Publication number: 20090036423Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.Type: ApplicationFiled: February 1, 2008Publication date: February 5, 2009Inventors: Shifeng Pan, Wenqi Gao, Nathanael S. Gray, Yuan Mi, Yi Fan
-
Publication number: 20090036513Abstract: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, and Pichinde), Filoviridae (Ebola and Marburg viruses), Flaviviridae (yellow fever, Omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever).Type: ApplicationFiled: March 2, 2007Publication date: February 5, 2009Applicant: SIGA TECHNOLOGIES, INC.Inventors: Dennis E. Hruby, Tove C. Bolken, Sean Amberg, Dongcheng Dai
-
Publication number: 20090036420Abstract: The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.Type: ApplicationFiled: July 28, 2008Publication date: February 5, 2009Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20090030065Abstract: The present invention relates to the use of PDE1C as a novel target for the identification of compounds, which can be used for the treatment of pulmonary hypertension, fibrotic lung diseases or other fibrotic diseases outside the lung. The present invention further relates to the use of PDE1C inhibitors in the manufacture of pharmaceutical compositions for use in the therapy of those diseases.Type: ApplicationFiled: June 13, 2006Publication date: January 29, 2009Applicant: NYCOMED GmbHInventors: Torsten Dunkern, Armin Hatzelmann, Friedrich Grimminger, Ralph Schermuly
-
Publication number: 20090004279Abstract: A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition.Type: ApplicationFiled: September 10, 2008Publication date: January 1, 2009Inventors: Thomas Hofmann, Alan Bruce Montgomery, Kevin Stapleton, William R. Baker
-
Publication number: 20080317846Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: ApplicationFiled: July 11, 2008Publication date: December 25, 2008Inventors: Phillip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Publication number: 20080319057Abstract: 2-Phenylethylamino substituted carboxamide derivatives of formula (I); wherein J, W, R0, R1, R2, R3, and R4 have the meanings as defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urology, and gastrointestinal diseases where the above mechanisms have been described as playing a pathological role, are described.Type: ApplicationFiled: November 29, 2006Publication date: December 25, 2008Inventors: Florian Thaler, Mauro Napoletano, Cibele Sabido-David, Ermanno Moriggi, Carla Caccia, Laura Faravelli, Alessandra Restivo, Patricia Salvati
-
Publication number: 20080318881Abstract: The present invention includes a fast-drying liquid composition comprising at least one fungicide and at least one insecticide. The present invention further includes a method for treating plant propagation materials, especially cut seeds, including tubers, against pests, a method for promoting suberization in cut seeds, a method for decreasing the drying time of a liquid pesticide on cut seeds, and a method for selectively loading a pesticide onto the skin side of a cut seed.Type: ApplicationFiled: June 28, 2006Publication date: December 25, 2008Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Marlene Torrent-Parker, Kiran Shetty
-
Patent number: 7468360Abstract: Disclosed herein is a compound having a structure: Therapeutic methods, compositions, and medicaments relating thereto are also disclosed.Type: GrantFiled: August 8, 2007Date of Patent: December 23, 2008Assignee: Allergan, Inc.Inventors: David W. Old, Danny T. Dinh
-
Patent number: 7468449Abstract: The present invention relates to novel, non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1?,25dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.Type: GrantFiled: November 16, 2004Date of Patent: December 23, 2008Assignee: Eli Lilly and CompanyInventors: Robert Peter Gajewski, Charles David Jones, Jianliang Lu, Tianwei Ma, Sunil Nagpal, Ying Kwong Yee
-
Patent number: 7465718Abstract: Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have expected merit in rendering the overall compounds useful as drugs and prodrugs.Type: GrantFiled: February 10, 2003Date of Patent: December 16, 2008Assignee: Conforma Therapeutics CorporationInventors: Lin Zhang, Jean-Yves Le Brazidec, Lawrence C. Fritz, Francis J. Burrows, Marcus F. Boehm, Junhua Fan, Sean Konrad McHugh
-
Publication number: 20080306117Abstract: A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii) an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.Type: ApplicationFiled: August 5, 2008Publication date: December 11, 2008Applicant: Asterand UK LimitedInventors: David Edward Clark, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark
-
Publication number: 20080306146Abstract: The present invention relates to a potent cyclooxygenase-2 inhibitor and dosing regimens thereof to safely treat cyclooxygenase-2 mediated disorders.Type: ApplicationFiled: October 31, 2006Publication date: December 11, 2008Applicant: AMOREPACIFIC CORPORATIONInventors: Kyung-Min Lim, Mi-Young Park, Kl-Wha Lee, Sung-ll Kim, Shin Chung
-
Publication number: 20080306041Abstract: The invention describes compositions and kits comprising at least one cardiovascular compound comprising at least one heterocyclic nitric oxide donor group, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; (k) treating nephropathy; (l) treating peripheral vascular diseases; (m) treating portal hypertension and (n) treating ophthalmic disorders. The cardiovascular compounds are preferably ?-adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors, anti-hyperlipidemic compounds, and antithrombotic and vasodilator compounds.Type: ApplicationFiled: January 23, 2006Publication date: December 11, 2008Inventor: David S. Garvey
-
Publication number: 20080300240Abstract: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R1, R2, R3, R4, R5, A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.Type: ApplicationFiled: May 20, 2008Publication date: December 4, 2008Applicant: Omeros CorporationInventors: John E. Bergmann, Neil S. Cutshall, Rene Onrust, Hongkui Zeng, Jennifer Lynn Gage, Derek Johnston, Sandor Cseh, Laszlo Urogdi, Akos Papp
-
Publication number: 20080293808Abstract: Non-steroidal androgen receptor modulating compounds of the general formula (I), their pharmaceutically acceptable salts, preparation process and pharmaceutically compositions containing the said compounds are disclosed. Such compounds of the general formula (I) or their pharmaceutically acceptable salts can be used for preparing non-steroidal medicines to treat and/or prevent conditions or diseases such as prostatic hyperplasia, prostate cancer, hirsutism, severe hormone-dependent alopecia or acne, etc. as a result of androgen receptor antagonistic activities.Type: ApplicationFiled: May 26, 2006Publication date: November 27, 2008Inventors: Mingwei Wang, Caihong Zhou, Xin Hui, Haoran Su, Jie Gao, Yong Deng, Dacheng Yang
-
Publication number: 20080293722Abstract: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein can be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel subtype targets.Type: ApplicationFiled: March 15, 2005Publication date: November 27, 2008Applicant: WyethInventors: Robert Zelle, Christopher Todd Baker, Paul Will, Vincent P. Galullo
-
Publication number: 20080287425Abstract: The present invention relates to a method for controlling chinch bugs comprising introducing to a locus where chinch bug control is needed or expected to be needed a composition comprising a nitroguanidine insecticide.Type: ApplicationFiled: February 9, 2006Publication date: November 20, 2008Applicant: FMC CORPORATIONInventors: Kim Watson, Robert Herrick
-
Publication number: 20080279822Abstract: The present invention relates to four distinct crystalline polymorphs of a monohydrate of Compound A having the following chemical structure: Compound A. These four polymorphic forms, herein referred to as Forms I, II III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.Type: ApplicationFiled: July 16, 2008Publication date: November 13, 2008Inventors: Mengwei Hu, Younong Yu, Michael Dwyer, Arthur Taveras, Agnes Kim-Meade, Jianguo Yin, Xiaoyong Fu, Timothy McAllister, Shuyi Zhang, Kevin Klopfer
-
Publication number: 20080269161Abstract: Provided is a method of protecting a neuron from dysfunction induced by an HIV neurotoxin comprising contacting the cell with a therapeutically effective dose of an inhibitor of mitochondrial hyperpolarization.Type: ApplicationFiled: January 19, 2006Publication date: October 30, 2008Inventors: Seth Perry, John Phillip Norman, Stephen Dewhurst, Harris A. Gelbard
-
USE OF 4-(NITROOXY)-BUTYL-(S)-2-(6-METHOXY-2-NAPHTHYL)-PROPANOATE FOR TREATING PAIN AND INFLAMMATION
Publication number: 20080269323Abstract: The present invention relates to the use of 4-(Nitrooxy)-butyl-(S)-2-(6-methoxy-2-naphthyl)-propanoate (naproxcinod) for treating pain and inflammation, in particular musculo-skeletal disorders, in patients with congestive heart failure, liver disease, cirrhosis, pre-existing renal disease, volume depletion, elderly with renal impairment, chronic renal failure or essential hypertension.Type: ApplicationFiled: April 23, 2008Publication date: October 30, 2008Applicant: NICOX S.A.Inventors: Pottumarthi V. PRASAD, Manlio Bolla, Marianna Armogida -
Publication number: 20080260837Abstract: The present invention concerns methods of making physically stable aqueous suspensions of sparingly soluble to insoluble in water, active pharmaceuticals. More particularly, the invention provides an aqueous pharmaceutical suspension composition comprising an active pharmaceutical component which is sparingly soluble to insoluble in water; a water soluble, low viscosity grade cellulose polymer with a viscosity range of 3 mPa·s to 50 mPa·s as a surfactant; a suspending agent; and water.Type: ApplicationFiled: April 20, 2007Publication date: October 23, 2008Inventors: Ranga R. Namburi, Bala Murali K. Vattikuti, Ratna Prabha Mulamalla, Burgise F. Palkhiwala
-
Publication number: 20080261967Abstract: Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents.Type: ApplicationFiled: June 20, 2005Publication date: October 23, 2008Inventor: John Cashman
-
Publication number: 20080262086Abstract: Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.Type: ApplicationFiled: April 18, 2008Publication date: October 23, 2008Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20080261810Abstract: Insecticidal compositions, characterized by an effective amount of a combination of active compounds comprising (a) at least one compound of the formula (I) in which Het, A, R and X are as defined in the description, and (b) at least one crop plant compatibility-improving compound from the group of compounds listed in the description, which are used for controlling arthropods, and also methods for controlling arthropods by treating plants and their seed with said compositions.Type: ApplicationFiled: July 18, 2005Publication date: October 23, 2008Inventors: Reiner Fischer, Wolfram Andersch, Heike Hungenberg, Wolfgang Thielert, Lothar Willms
-
Publication number: 20080255095Abstract: A compound of the formula (I): wherein R1 is C1-C6 alkyl, amino, (C1-C6 alkyl)amino, di(C1-C6 alkyl)amino or a nitrogen-containing saturated heterocyclic; R2 and R3 are hydrogen or C1-C6 alkyl; Arom is phenyl, idenyl, napthyl, phenanthrenyl, furyl, thiolyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3 oxadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or quinolyl; A is C1-C6 alkylene; Ra is hydrogen, C1-C6 alkyl or C2-C6 alkenyl; E is a single bond, oxygen, sulfur or —NR4—, wherein R4 is hydrogen or C1-C7 alkanoyl; X1 and X2 are oxygen or sulfur; or a pharmacologically acceptable salt or ester thereof.Type: ApplicationFiled: June 18, 2007Publication date: October 16, 2008Applicant: BTG INTERNATIONAL LIMITEDInventors: Kazuo Koyama, Shinji Marumoto, Narihiro Toda, Hiroshi Kogen, Keiko Suzuki
-
Publication number: 20080249107Abstract: Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols, indices and substituents have the following meaning R1?H, CN, NO2, CF3, F, Cl, Br, I, CH3 R2?H, CN, NO2, CF3, F, Cl, Br, I, CH3, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl and either R1 or R2 must be H R3?H, CN, NO2, CF3, F, Cl, Br, I, CH3, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl then X is e.g. with R4 being H, CH3, CH2CH3 or and Y being or the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formulas (Ia) or (Ib). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.Type: ApplicationFiled: March 18, 2005Publication date: October 9, 2008Applicant: REVOTAR BIOPHARMACEUTICALS AGInventors: Remo Kranich, Ewald Mirko Aydt
-
Publication number: 20080242682Abstract: A combination of (S)—N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide with a medicine capable of prolonging a slow-wave sleep time provides a preventive or therapeutic agent for sleep disorder that induces natural sleep, shortens sleep latency, increases deep sleep, excels in sleep maintenance and ensures an appropriate sleep time.Type: ApplicationFiled: December 12, 2005Publication date: October 2, 2008Applicant: Takeda Pharmaceutical Company LimitedInventors: Keisuke Hirai, Masaomi Miyamoto
-
Patent number: 7429390Abstract: The present invention is generally related to alcohol free, liquid ranitidine formulations for oral administration. In particular, the present invention is related to stable, syrup formulations having ranitidine as an active ingredient for oral administration, processes for making the same, and methods of their use. The ranitidine of the present invention is stable in non-polar media or media having a relatively low polarity such that the dielectric constant is less than about 60, and is achieved by using certain saccharides, certain relatively high molecular weight starches, and/or certain celluloses instead of alcohol.Type: GrantFiled: May 2, 2007Date of Patent: September 30, 2008Inventor: Nagesh R. Palepu
-
Publication number: 20080234331Abstract: The invention relates to insecticidal mixtures containing, as active substances, at least two compounds from the series of the chloronicotinyl insecticides, and to the use of these mixtures for promoting plant growth.Type: ApplicationFiled: October 30, 2006Publication date: September 25, 2008Applicant: Bayer CropScience AGInventors: Klaus Fellmann, Bernd Springer
-
Publication number: 20080234328Abstract: An aqueous composition suitable for applying insecticides or acaricides to plant propagation materials comprising water, an insecticidally or acaricidally effective amount of at least one nitroimino- or nitroguanidino-compound in free form or in agrochemically useful salt form and a blend of the following components, by weight: a) 2-10% of a surface-active agent comprising a1) at least one anionic surfactant; b) 4-20% of at least one inorganic solid carrier; and c) 3-25% of at least one antifreeze agent. In one embodiment, the aqueous composition further comprises a fungicidally effective amount of at least one fungicidally active compound. The inventive composition is storage stable, ready-to-apply (RTA), ecologically and toxicologically favorable and has good fungicidal efficacy.Type: ApplicationFiled: October 30, 2007Publication date: September 25, 2008Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Christian Schlatter, Ravi Ramachandran
-
Publication number: 20080220066Abstract: An anti-viral topical gel formulation comprising at least one loop diuretic and/or cardiac glycoside in a gel carrier medium, said formulation capable of transdermal delivery of the said diuretic and/or glycoside.Type: ApplicationFiled: August 22, 2006Publication date: September 11, 2008Applicant: HENDERSON MORLEY PLCInventors: Christopher Hartley, Ian Stuart Pardoe
-
Patent number: 7423057Abstract: The present invention relates to a novel compounds that can be used as anti-inflammatory, immunomodulatory and antiproliferatory agents. In particular, the invention refers to new compounds which inhibit dihydroorotate dehydrogenase (DHODH), a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehyrogenase (DHODH).Type: GrantFiled: February 17, 2006Date of Patent: September 9, 2008Assignee: 4SC AGInventors: Johan Leban, Bernd Kramer, Wael Saeb, Gabriel Garcia
-
Patent number: 7423170Abstract: Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.Type: GrantFiled: January 23, 2006Date of Patent: September 9, 2008Assignee: Arizona Biomedical Research CommissionInventors: Seth D. Rose, Scott R. Lefler, Steven R. Ottersberg, Ann Y. Kim, Karl J. Okolotowicz, Rosemarie F. Hartman
-
Patent number: 7417057Abstract: It has now been found that certain novel heterocyclic derivatives have provided unexpected insecticidal activity. These compounds are represented by formula (I): R Preferred are those compounds of formula (I) where R2 and R3 taken together is ?NCH(R6)CH(R7)N(R8)—, ?NC(R6)?C(R7)N(R8)—, or ?CHN?C(R7)N(R8)—, and tautomers thereof, and where R4 and R5 taken together is —C(R11)?C(R12)C(R13)?C(R14) 1 12, —, where R,R,R 6, R 7, R8, R I1, R R 13, R 14, and X are described.Type: GrantFiled: April 28, 2003Date of Patent: August 26, 2008Assignee: Bayer Cropscience AGInventors: John A. Dixson, Zeinab M. Elshenawy, Harvey R. Wendt, Saroj Sehgel, Robert H. Henrie, II, David M. Roush, Ping Ding, John W. Lyga, Stephen F. Donovan
-
Patent number: 7414073Abstract: Included within the scope of the present invention are potent taxanes and taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in selected cell populations comprising: (A) a cytotoxic amount of one or more taxanes covalently bonded to a cell binding agent through a link, and (B) a pharmaceutically acceptable carrier, diluent or excipient is also included. A method for inducing cell death in selected cell populations comprising contacting target cells or tissue containing target cells with an effective amount of a cytotoxic agent comprising one or more taxanes linked to a cell binding agent is included as well.Type: GrantFiled: October 14, 2004Date of Patent: August 19, 2008Assignee: Immunogen Inc.Inventors: Erkan Baloglu, Michael Miller, Ravi V. J. Chari
-
Publication number: 20080194650Abstract: The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha2 adrenergic receptors.Type: ApplicationFiled: December 5, 2007Publication date: August 14, 2008Inventors: Ken Chow, Wenkui K. Fang, Evelyn G. Corpuz, Daniel W. Gil, Michael E. Garst
-
Publication number: 20080194536Abstract: The present invention relates to a compound represented by the following formula: (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, or a combination thereof, wherein Ro, R1, R1?, R2, R2?, R3 and n are defined herein. The present invention further relates to a method of treating a patient from endometreosis or uterine fibroids.Type: ApplicationFiled: April 14, 2006Publication date: August 14, 2008Inventors: Marlys Hammond, David G. Jones, Istvan Kaldor, Lara S. Kallander, Xi Lang, Scott Kevin Thompson, Philip Stewart Turnbull, David G. Washburn
-
Publication number: 20080176938Abstract: The present invention relates to the use of compounds of the general Formula (1): wherein in Formula (1), R is H, alkyl, cycloalkyl, aryl or heteroaryl; R1 is H, alkyl, cycloalkyl, aryl or heteroaryl; R2 is H, alkyl, cycloalkyl, aryl or heteroaryl; A1 and A2 each independently represent an optionally substituted C1-C20-alkyl group which may contain one or more group(s) Z, or a monocyclic or polycyclic optionally substituted aromatic or non-aromatic ring system which may contain one or more group(s) X, and in case of a polycyclic ring system, said system contains at least one aromatic ring; Z is selected from the group consisting of S, O, N, NR4, CO, CO2, CS, SO or SO2 X is selected from the group consisting of S, O, N, NR4, SO or SO2.Type: ApplicationFiled: December 28, 2007Publication date: July 24, 2008Inventors: Aldo Ammendola, Katharina Aulinger-Fuchs, Astrid Gotschlich, Bernd Kramer, Martin Lang, Wael Saeb, Udo Sinks, Andreas Wuzik
-
Publication number: 20080171783Abstract: The present disclosure provides amide-based, non-nucleoside compounds having an inhibitory activity against endogenous polymerases, such as polymerase alpha and polymerase gamma. This disclosure further provides uses of treating hyperproliferative diseases or disorders, such as benign or malignant neoplasms, and more specifically cancers that are sensitive to inhibition of polymerase alpha and polymerase gamma.Type: ApplicationFiled: December 28, 2007Publication date: July 17, 2008Applicant: Migenix Inc.Inventors: Dale Russell Cameron, Maria Marta Guarna, Luba Metlitskaia
-
Publication number: 20080166378Abstract: Methods of identifying death receptor sensitizing compounds and methods of using death receptor sensitizing compounds are provided.Type: ApplicationFiled: January 11, 2007Publication date: July 10, 2008Inventors: Aaron D. Schimmer, John C. Reed
-
Publication number: 20080166407Abstract: Multifunctional, single, bilayer, and trilayer coated tablets for combination therapy are formed wherein the bioactive agents responsible for the therapeutic multifunctionality are present as a combination of a gastric acid-reducing agent, such as omeprazole and ranitidine, and at least one analgesic/anti-inflammatory agent, such as acetaminophen, naproxen sodium, ibuprofen, tolmetin, and aspirin.Type: ApplicationFiled: February 21, 2008Publication date: July 10, 2008Inventors: Shalaby W. Shalaby, Kenneth David Gray, Joel T. Corbett
-
Publication number: 20080166310Abstract: A regime or regimen for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for preventing and/or limiting the depigmentation and/or bleaching and/or for preventing and/or limiting the canities thereof, more particularly of human keratin fibers such as the hair, beard hair, moustache hair, the eyelashes and the eyebrows, includes administering to an individual in need of such treatment at least one 2-oxyacetamide compound of formula (I), or a salt and/or solvate thereof:Type: ApplicationFiled: December 10, 2007Publication date: July 10, 2008Applicant: L'OREALInventors: Roger Rozot, Philippe Breton, Michel Neuwels, Christophe Boulle
-
Patent number: 7396858Abstract: Diabetes treatments comprising, as effective ingredients, biguanide derivatives represented by the following general formula (1), or salts thereof. (wherein R1, R2 and R3 may be the same or different and each represents one selected from the group consisting of hydrogen, optionally substituted lower alkyl groups and optionally substituted lower alkylthio groups).Type: GrantFiled: April 22, 2003Date of Patent: July 8, 2008Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Naoki Taka, Hiroharu Matsuoka
-
Publication number: 20080161390Abstract: (5-Benzl-3-furyl)methyl 2,2-dimethyl-3-((E)-2-cayano-3-methoxy-3-oxo-1-propenyl)cyclopropanecarboxylate has an excellent pesticidal activity, and a pesticidal composition comprising it as an active ingredient is useful for controlling pests.Type: ApplicationFiled: February 8, 2005Publication date: July 3, 2008Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Tatsuya Mori